Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MedAdvisor Limited ( (AU:MDR) ) just unveiled an announcement.
MedAdvisor Limited reported a decline in revenue and gross profit for the fourth quarter and full fiscal year 2025, attributed to budgetary pressures and delayed health program rollouts. Despite these challenges, the company completed a successful capital raise and accelerated its Transformation 360 initiative to improve future performance. The sale of its ANZ business to Jonas Software for $35 million has left MedAdvisor debt-free, and the company is considering strategic options, including a potential sale of its US business. The deferred revenue and a strong pipeline of US$125 million provide confidence for a solid first half of fiscal year 2026.
The most recent analyst rating on (AU:MDR) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
More about MedAdvisor Limited
MedAdvisor Limited operates in the healthcare technology industry, focusing on pharmacy technology services. The company provides solutions that enhance medication management and improve patient outcomes, with a market focus on both the Australian and US healthcare sectors.
Average Trading Volume: 1,193,344
Technical Sentiment Signal: Sell
Current Market Cap: A$48.14M
For detailed information about MDR stock, go to TipRanks’ Stock Analysis page.